HCQ Lipid 4（HCQ-4）
Version 1.1cec4b3c · 2026-09-13
| CAS No. | Not available |
| Chemical Name | HCQ Lipid 4（HCQ-4） |
| Synonyms | HCQ-Lipid-4，Lipid 4 |
| SMILES | CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(=O)CCC(=O)OCCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1 |
| Formula | C50H87O3ClN4 |
| M.Wt | 827.72 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
HCQ-4 is a rationally engineered ionizable lipid derived from hydroxychloroquine (HCQ), featuring a ditetradecylamine-derived twin-C14 saturated hydrocarbon tail linked to the HCQ headgroup via a succinic acid spacer. Synthesized through a three-step route involving HCQ deprotonation, ditetradecylamine carboxylation, and EDC/DMAP-mediated amidation, this lipid forms the core of optimized lipid nanoparticles (LNPs) at a molar ratio of 60:10:40:0.5 (HCQ-4:DOPE:cholesterol:DMG PEG<sub>2000</sub>). The structure enables dual functionality: (1) Spleen-selective mRNA delivery (2.3-fold higher splenic vs. hepatic transfection) via 80-100 nm particle size, near-neutral charge (-3 mV), and low PEG density, facilitating immune cell uptake; (2) Tumor microenvironment modulation through HCQ-mediated repolarization of M2 macrophages to antitumor M1 phenotype (iNOS<sup>+</sup> cells ↑2.5-fold, CD206<sup>+</sup> cells ↓60%). This bifunctional design synergistically enhances mRNA cancer vaccine efficacy, demonstrating superior prophylactic/therapeutic antitumor activity and antimetastatic effects compared to clinical benchmarks like MC-3 LNP.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →